Lupus & antiphospholipid syndrome
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
Primary result · SRI-4 responseResult — go to the resultOdds ratio 1.04 95% CrI 0.74–1.45Authors' conclusion
Our results suggest that the SRI-4 response of belimumab and anifrolumab are similar at 52 weeks in the general SLE population, but the level of uncertainty around the point estimate means we cannot rule out the possibility of a clinically meaningful benefit for either treatment.
Study context
- Population
- Adults with SLE in randomised trials8 trials
- Comparison
- Belimumab vs anifrolumab
- Primary endpoint
- SRI-4 response
- Follow-up
- 52 weeks
Methodological detailssystematic literature review, multilevel network meta-regression (ML-NMR) adjusted for SLEDAI-2K, anti-dsDNA positivity, low C3 and low C4, sensitivity analyses
- Systematic literature review
- ML-NMR adjusted for SLEDAI-2K, anti-dsDNA positivity, low C3 and low C4
- Sensitivity analyses
Primary result
As reported in the abstract
Odds ratio
1.04
95% CrI 0.74–1.45
Belimumabvs Anifrolumab
OR 1.04 (95% CrI 0.74–1.45)
- Probability belimumab is the more effective treatment
- 0.58
Further findings
Robustness across analysis scenarios
- Results highly consistent across all analysis scenarios
Original publication
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus Sci Med. Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →